EX
EXOZ.US eXoZymes, Inc.
- Market cap
- USD 35.6M
- P/E
- -
- P/B
- 10.19x
- ROE
- -455.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EXOZ.US undervalued?
Graham numberThe Graham number of eXoZymes, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
eXoZymes, Inc. fundamental analysis
No fundamental analysis for eXoZymes, Inc. yet.
eXoZymes, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Full company profileeXoZymes, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
eXoZymes, Inc. annual financial statements
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -59.4K | -148K | - | -267K | - | - |
| Operating Income | -1.29M | -1.33M | -1.80M | -5.93M | -9.72M | - |
| EBITDA | -1.15M | -1.18M | -1.80M | -5.59M | -8.98M | - |
| Net Income | -1.21M | -1.40M | -2.04M | -5.86M | -9.16M | -9.98M |
| EPS | -0.15 | -0.17 | -0.25 | -0.72 | -1.09 | -1.07 |
| Balance Sheet | ||||||
| Total Assets | 2.35M | 2.69M | 3.56M | 13.0M | 5.97M | 5.86M |
| Total Liabilities | 1.15M | 1.31M | 3.94M | 2.61M | 2.57M | 3.67M |
| Shareholders' Equity | 1.20M | 1.37M | -384K | 10.4M | 3.40M | 2.19M |
| Cash & Short-term Investments | 548K | 559K | 66.5K | 9.72M | 3.04M | 3.26M |
| Total Debt | 721K | 609K | 1.61M | 1.39M | 1.24M | 650K |
| Cash Flow | ||||||
| Operating Cash Flow | -1.59M | -1.26M | -1.18M | -8.51M | -6.50M | -7.18M |
| Capital Expenditure | 423K | 186K | 289K | 396K | 170K | 490K |
| Free Cash Flow | -2.01M | -1.44M | -1.47M | -8.90M | -6.67M | -7.67M |
| Ratios | ||||||
| ROE | -101.0% | -101.7% | - | -56.2% | -269.6% | -455.6% |
| ROA | -51.5% | -52.0% | -57.3% | -45.0% | -153.4% | -170.3% |
| Debt to Equity | 0.60x | 0.44x | - | 0.13x | 0.37x | 0.30x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
eXoZymes, Inc. dividends
eXoZymes, Inc. has not paid dividends in the last 5 fiscal years.
Who owns eXoZymes, Inc.
- Insiders 65.36%
- Institutions 1.26%
- Public & others 33.39%
- Shares outstanding 9.30M
- Free float 7.17M
Top funds holding EXOZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 86.4K | 0.93% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 11.7K | 0.13% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 10.4K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 2.94K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.02K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.00K | 0.02% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 404.00 | 0.00% | -50.12% | Sep 2026 |
Top institutions holding EXOZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 55.0K | 0.59% | +147.79% | Jun 2026 |
| Geode Capital Management, LLC | 23.4K | 0.25% | +6.92% | Jun 2026 |
| Davidson Kahn Capital Management, LLC | 18.0K | 0.19% | -28.00% | Sep 2026 |
| BlackRock Inc | 9.61K | 0.10% | +41.39% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 9.43K | 0.10% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.25K | 0.01% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 349.00 | 0.00% | -73.50% | Jun 2026 |
| Mercer Global Advisors Inc. | 250.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 203.00 | 0.00% | +745.83% | Jun 2026 |
| Barclays PLC | 75.00 | 0.00% | 0.00% | Jun 2026 |
eXoZymes, Inc. company profile
- Company name
- eXoZymes, Inc.
- Ticker
- EXOZ.US
- Exchange
- USA Stocks
- Listed since
- Nov 13, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Fiscal year end
- December
- Address
- 750 Royal Oaks Drive, Monrovia, CA, United States, 91016
- Phone
- 626 415 1488
- Website
- exozymes.com
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
eXoZymes, Inc. management
9- Mr. Michael HeltzenPresident & CEO · born 1981
- Dr. Tyler Korman Ph.D.Co-Founder & Chief Scientific Officer · born 1979
- Dr. Paul Opgenorth Ph.D.Co-Founder & Vice President of Development · born 1983
- Mr. James U. Bowie Ph.D.Founder & Independent Director · born 1959
- Mr. Fouad NawazVice President of Finance · born 1986
- Mr. Damien A. PerrimanChief Commercial Officer · born 1977
- Mr. Lasse H. GorlitzVice President of Communications
- Mr. Michael BurnsExecutive Vice President of Energy Transition
- Ms. Amy LunzerChief of Staff